Teva Pins Long-Term Hopes In MS On Return Of Laquinimod
This article was originally published in Scrip
Executive Summary
After missing out on the initial wave of oral multiple sclerosis drugs, Teva Pharmaceutical Industries Ltd. still has its eye on the oral immunomodulator laquinimod as a future pillar for the firm in multiple sclerosis. Teva is hoping for a launch in 2018 after a third and final Phase III trial reads out in 2017.